In the rapidly evolving world of gaming, 포지 네오포지 emerges as a groundbreaking phenomenon, pushing technological and creative boundaries to unprecedented new heights. This new concept, which translates to ‘Forge Neoforge’ in English, is not merely an update to traditional gaming, but potentially a paradigm shift that leverages the latest in artificial intelligence and immersive technologies. At its core, 포지 네오포지 integrates AI-driven gameplay that adapts and evolves based on players’ unique styles and skills. No longer bound by static storylines and predictable outcomes, players will find themselves navigating complex, dynamic worlds that respond and change in real time. This ability to shape gameplay according to individual input ensures a truly personalized experience and enhances player engagement. Moreover, 포지 네오포지 harnesses the power of cutting-edge virtual reality and augmented reality technologies. By blurring the lines between the digital and physical realms, players are transported into hyper-realistic environments where sensations and interactions are indistinguishable from reality. Imagine exploring fantastical landscapes where each decision influences the surrounding ecosystem and characters in tangible, consequential ways. As developers continue to refine this bold new frontier, 포지 네오포지 sets the stage for a future where gaming is not just entertainment but an immersive narrative journey redefining how we understand virtual interactivity. This revolutionary approach may very well place players at the helm of their interactive destinies, embedding them deeper into their own personalized stories than ever before. The gaming community eagerly awaits as 포지 네오포지 heralds the dawn of a new era. Discover the Future of Gaming: How 포지 네오포지 Revolutionizes Immersive Experiences The gaming industry stands on the cusp of a revolution with the emergence of 포지 네오포지, also known as ‘Forge Neoforge.’ This innovative project is transforming the landscape of digital entertainment by leveraging groundbreaking advancements in artificial intelligence, virtual reality, and augmented reality. Let’s delve into the unique attributes and implications of 포지 네오포지 that position it as a leader in next-gen gaming. Key Features of 포지 네오포지 1. Adaptive AI Integration : 포지 네오포지 features AI-driven gameplay that learns and evolves with each player, creating a bespoke gaming experience. This technology adapts to individual skill levels and decision-making styles, offering a dynamic and ever-changing narrative landscape. 2. Immersive VR and AR Experiences : By utilizing cutting-edge virtual and augmented reality technologies, 포지 네오포지 blurs the lines between digital and physical. Gamers can step into hyper-realistic environments where their actions have real-time consequences, deeply enhancing the sense of presence and interaction. 3. Personalized Storytelling : Gone are the days of linear storylines. 포지 네오포지 empowers players to influence narratives directly, making each gaming session unique. This personal approach fosters deeper emotional connections between players and the game world. Pros and Cons of 포지 네오포지 # Pros: – Enhanced Engagement : Adaptive elements increase player involvement and long-term engagement. – Cutting-edge Realism : VR and AR provide unparalleled immersion, making interactions more impactful. – Flexible Gameplay : Tailored experiences suit diverse player preferences and styles. # Cons: – Technical Requirements : Advanced hardware may be necessary to support enhanced features. – Learning Curve : New technologies may require time for players to adjust. Market Predictions and Trends As 포지 네오포지 pushes the boundaries of what is technically and creatively possible, analysts predict significant impacts on the gaming market, including: – Increased Demand for High-Tech Gear : As players seek to take full advantage of the immersive experiences offered, sales of VR and AR devices are anticipated to rise. – Expansion of Interactive Storytelling : The preference for personalized, player-driven narratives may influence game development trends across the industry. Sustainability and Future Innovations With an eye on sustainability, 포지 네오포지 developers are considering eco-friendly practices in both digital spaces and physical production. The continued evolution of AI and machine learning technologies promises further innovation in realistic simulations and adaptive gameplay features, positioning 포지 네오포지 at the forefront of future gaming revolutions. In conclusion, 포지 네오포지 embodies a bold step forward, combining cutting-edge technology with creative storytelling to craft unique, engaging gaming experiences. As the gaming community eagerly anticipates its full deployment, 포지 네오포지 is expected to significantly shape the industry’s future trajectory. For more information, visit the official websites of prominent gaming companies like [Valve Software](https://www.valvesoftware.com) or [Electronic Arts](https://www.ea.com) to explore their contributions to the evolving gaming landscape.Orla Mining Ltd. ( NYSEAMERICAN:ORLA – Free Report ) – Investment analysts at Cormark issued their FY2028 earnings estimates for Orla Mining in a research report issued to clients and investors on Tuesday, November 19th. Cormark analyst R. Gray expects that the company will earn $1.03 per share for the year. The consensus estimate for Orla Mining’s current full-year earnings is $0.23 per share. ORLA has been the subject of a number of other reports. Desjardins upgraded Orla Mining to a “moderate buy” rating in a research note on Thursday, October 31st. Scotiabank raised their price target on Orla Mining from $5.75 to $6.00 and gave the stock a “sector perform” rating in a report on Friday, October 11th. Orla Mining Stock Down 0.2 % NYSEAMERICAN ORLA opened at $4.59 on Thursday. The stock has a market capitalization of $1.47 billion, a PE ratio of -458.54 and a beta of 0.79. Orla Mining has a one year low of $2.60 and a one year high of $5.16. The company has a quick ratio of 3.95, a current ratio of 4.54 and a debt-to-equity ratio of 0.12. Institutional Investors Weigh In On Orla Mining Several large investors have recently made changes to their positions in the company. International Assets Investment Management LLC acquired a new stake in Orla Mining in the third quarter worth about $43,000. Kitching Partners LLC bought a new stake in shares of Orla Mining during the 3rd quarter worth about $48,000. Walleye Capital LLC acquired a new stake in shares of Orla Mining in the 3rd quarter worth approximately $69,000. DF Dent & Co. Inc. bought a new position in shares of Orla Mining in the third quarter valued at approximately $80,000. Finally, Renaissance Technologies LLC acquired a new position in shares of Orla Mining during the second quarter valued at approximately $102,000. Institutional investors and hedge funds own 43.04% of the company’s stock. About Orla Mining ( Get Free Report ) Orla Mining Ltd. acquires, explores, develops, and exploits mineral properties. The company explores for gold, silver, zinc, lead, and copper deposits. It owns 100% interests in the Camino Rojo project that consists of seven concessions covering an area of 138,636 hectares located in Zacatecas, Mexico; Cerro Quema project totaling an area of 15,000 hectares located in the Azuero Peninsula, Panama; and the South Railroad project consisting of an area of 21,000 hectares located in Elko, Nevada. See Also Receive News & Ratings for Orla Mining Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orla Mining and related companies with MarketBeat.com's FREE daily email newsletter .

ST. PAUL, Minn. (AP) — Hope Adebayo rushed for 123 yards and two scores, Tak Tateoka threw a touchdown pass and St. Thomas-Minnesota rolled to a 32-9 victory over Dayton on Saturday in a season finale. Dayton scored first on a 24-yard field goal by Danny Baker, but the Tommies (6-6, 5-3 Pioneer Football League) responded with 25 unanswered points on its way to a 22-point advantage at halftime. Adebayo gave the Tommies the lead with an 11-yard touchdown run. Tateoka connected with Colin Chase for a 42-yard score and a 14-3 lead early in the second quarter. Ryan Calcagno returned a fumble 34 yards for a touchdown and senior defensive back Grif Wurtz ran it in for the two-point conversion. Ben Holland kicked a 31-yard field goal with 68 seconds left before intermission. Adebayo bulled his way into the end zone on the first play of the fourth quarter to up the Tommies' lead to 32-3. Drew VanVleet threw a 13-yard touchdown pass to Jake Coleman late to complete the scoring for the Flyers (6-5, 4-4). Tateoka completed 12 of 21 passes for 136 yards with one interception for St. Thomas-Minnesota. Adebayo did his damage on 22 carries. Chase finished with seven receptions for 101 yards. VanVleet totaled 198 yards on 23-for-43 passing with three interceptions. Coleman caught 10 passes for 107 yards. Get poll alerts and updates on the AP Top 25 throughout the season. Sign up here . AP college football: https://apnews.com/hub/ap-top-25-college-football-poll and https://apnews.com/hub/college-footballCIBC Asset Management Inc purchased a new position in shares of Halozyme Therapeutics, Inc. ( NASDAQ:HALO – Free Report ) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 3,691 shares of the biopharmaceutical company’s stock, valued at approximately $211,000. A number of other large investors have also modified their holdings of HALO. O Shaughnessy Asset Management LLC increased its stake in shares of Halozyme Therapeutics by 4.6% in the first quarter. O Shaughnessy Asset Management LLC now owns 12,067 shares of the biopharmaceutical company’s stock valued at $491,000 after purchasing an additional 536 shares during the period. CANADA LIFE ASSURANCE Co increased its position in Halozyme Therapeutics by 29.5% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 130,856 shares of the biopharmaceutical company’s stock valued at $5,321,000 after acquiring an additional 29,845 shares during the period. Shell Asset Management Co. raised its stake in Halozyme Therapeutics by 30.4% during the 1st quarter. Shell Asset Management Co. now owns 11,199 shares of the biopharmaceutical company’s stock valued at $456,000 after acquiring an additional 2,611 shares in the last quarter. Advisors Asset Management Inc. boosted its position in Halozyme Therapeutics by 6.2% during the 1st quarter. Advisors Asset Management Inc. now owns 43,059 shares of the biopharmaceutical company’s stock worth $1,752,000 after acquiring an additional 2,505 shares during the period. Finally, Epoch Investment Partners Inc. grew its stake in shares of Halozyme Therapeutics by 23.3% in the first quarter. Epoch Investment Partners Inc. now owns 1,433,612 shares of the biopharmaceutical company’s stock worth $58,319,000 after purchasing an additional 270,579 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock. Analyst Upgrades and Downgrades Several equities research analysts recently weighed in on HALO shares. Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Wells Fargo & Company lowered shares of Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and upped their price target for the stock from $58.00 to $62.00 in a research note on Monday, October 7th. Benchmark reiterated a “buy” rating and set a $60.00 price objective on shares of Halozyme Therapeutics in a research note on Thursday, August 8th. JMP Securities upped their target price on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research report on Friday, November 1st. Finally, JPMorgan Chase & Co. lowered Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and increased their price target for the company from $52.00 to $57.00 in a research note on Thursday, September 19th. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $61.11. Halozyme Therapeutics Trading Up 7.2 % Shares of NASDAQ HALO opened at $49.00 on Friday. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. Halozyme Therapeutics, Inc. has a 12 month low of $33.15 and a 12 month high of $65.53. The company has a market cap of $6.23 billion, a price-to-earnings ratio of 16.18, a P/E/G ratio of 0.41 and a beta of 1.29. The business has a fifty day simple moving average of $54.85 and a 200-day simple moving average of $53.42. Insiders Place Their Bets In other Halozyme Therapeutics news, CEO Helen Torley sold 10,000 shares of the business’s stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $59.09, for a total transaction of $590,900.00. Following the sale, the chief executive officer now directly owns 676,744 shares of the company’s stock, valued at $39,988,802.96. The trade was a 1.46 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink . In the last quarter, insiders have sold 60,000 shares of company stock worth $3,425,000. Company insiders own 2.40% of the company’s stock. Halozyme Therapeutics Profile ( Free Report ) Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Read More Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. ( NASDAQ:HALO – Free Report ). Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .

Poll lessons for the BJP and CongressTikTok Is Running Out of Options. Trump May Be Its Best Hope for Survival

NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) (the “Company”), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it has drawn down the final tranche of €5 million (“Tranche C”) under the credit facility agreement for up to €40 million entered into with the European Investment Bank (the “EIB) on December 28, 2022 (the "Finance Contract"). With the drawdown of Tranche C, the Company has drawn down the full €40 million available under the Finance Contract. Tranche C is expected to be disbursed by the EIB by December 18, 2024. The Company plans to use the proceeds of Tranche C towards the development of its pipeline of allogeneic CAR T-cell product candidates: UCART22 and UCART20x22. As a condition to the disbursement of Tranche C the Company issued 611,426 warrants to the benefit of the EIB, in accordance with the terms of the 14th resolution of the shareholders’ meeting held on June 28, 2024 and articles L. 228-91 and seq. of the French Commercial Code (the “Tranche C Warrants”). Each Tranche C Warrant allows the EIB to subscribe for one ordinary share of the Company, at a price of €1.70, corresponding to 99% of the volume-weighted average price of the Company’s ordinary shares over the last 3 trading days preceding the decision of the board of directors of the Company to issue the Tranche C Warrants. The total number of shares issuable upon exercise of the Tranche C Warrants represent circa 0.6% of the Company’s outstanding share capital as at their issuance date. Tranche C will mature six years from its disbursement date and will accrue interest at a rate of 6% per annum capitalized annually and payable at maturity. The other terms of the Tranche C Warrants and prepayment events of Tranche C under the Finance Contract are as set forth in the Company’s press release of April 4, 2023 and Form 6-K filed with the U.S. Securities and Exchange Commission on such date. About Cellectis Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to make therapeutic gene editing in hemopoietic stem cells for various diseases. As a clinical-stage biopharmaceutical company with 25 years of experience and expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to treat diseases with unmet medical needs. Cellectis’ headquarters are in Paris, France, with locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more, visit our website: www.cellectis.com Follow Cellectis on social networks @cellectis on LinkedIn and X (formerly Twitter) TALEN® is a registered trademark owned by Cellectis. Cautionary Statement This press release contains “forward-looking” statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as “expect,” “plan,” and “will,” or the negative of these and similar expressions. These forward-looking statements, which are based on our management’s current expectations and assumptions and on information currently available to management. Forward-looking statements include statements about the date of disbursement of the Tranche C and the use of the proceeds of amounts received under the Finance Contract. These forward-looking statements are made in light of information currently available to us and are subject to numerous risks and uncertainties, including with respect to the numerous risks associated with market conditions, and our ability to satisfy the conditions precedent under the Finance Contract. Furthermore, many other important factors, including those described in our Annual Report on Form 20-F as amended and in our annual financial report (including the management report) for the year ended December 31, 2023 and subsequent filings Cellectis makes with the Securities Exchange Commission from time to time, which are available on the SEC’s website at www.sec.gov , as well as other known and unknown risks and uncertainties may adversely affect such forward-looking statements and cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. For further information on Cellectis, please contact: Media contacts: Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33, media@cellectis.com Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93 Investor Relations contact: Arthur Stril, Interim Chief Financial Officer, investors@cellectis.com Attachment